The growing prevalence for performance-enhancing peptides has created a significant grey market, posing both novel possibilities and considerable risks. These shadowy products, often obtained from overseas laboratories, bypass standard pharmaceutical channels, permitting purchase at reduced prices. However, the shortage of quality control and strin